Biofrontera Wins Patent Case, Sun Pharma Patent Ruled Unpatentable
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy BFRI?
Biofrontera announced that on February 23, 2026, the U.S. Patent Trial and Appeal Board issued a Final Written Decision finding all challenged claims of Sun Pharmaceutical Industries, Inc.'s U.S. Patent No. 11,697,028 to be unpatentable. As previously disclosed in Biofrontera's filings with the Securities and Exchange Commission, in June 2024, Sun Pharma initiated proceedings against Biofrontera and certain of its affiliates in the U.S. District Court for the District of Massachusetts and the International Trade Commission alleging infringement of the '028 Patent and a related patent, U.S. Patent No. 11,446,512. In response to these proceedings, Biofrontera challenged the validity of Sun Pharma's asserted claims by filing petitions for Inter Partes Review with the Board. The Board has now agreed with Biofrontera on all challenged claims of the '028 Patent. Sun Pharma has the right to request a review of the decision or appeal it to the United States Court of Appeals for the Federal Circuit. The decision does not affect the petition filed by the Company relating to the '512 patent, which was denied review by the Patent Office on administrative, rather than substantive, grounds. "Biofrontera is pleased with the Board's Final Written Decision.," commented Hermann Luebbert, CEO and Chairman of Biofrontera. "We remain focused on clinical research and development in the PDT space to better serve clinicians and improve their patients' lives."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BFRI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BFRI
Wall Street analysts forecast BFRI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.779
Low
3.00
Averages
6.00
High
9.00
Current: 0.779
Low
3.00
Averages
6.00
High
9.00
About BFRI
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biofrontera Reports Record Q4 2025 Revenue of $17.1M
- Significant Revenue Growth: Biofrontera reported Q4 2025 revenue of $17.1 million, a 36% year-over-year increase, indicating strong market demand and sales performance, which further solidifies its position in the dermatology treatment sector.
- Gross Margin Improvement: The company achieved a gross margin of 82.4%, primarily due to an improved cost structure following its transaction with Biofrontera AG, which not only enhances profitability but also provides funding for future investments and expansion.
- Net Income Turnaround: The net income for Q4 was $5.6 million, compared to a loss in the previous year, reflecting improved operational efficiency and financial health, which boosts investor confidence.
- Positive Future Outlook: Management expects to achieve profitability and cash flow breakeven in 2026, indicating confidence in sustained growth and plans to optimize operations and market strategies to reach this goal.
See More
Biofrontera Reports Record Revenue in FY 2025 Earnings Call
- Significant Revenue Growth: Biofrontera achieved record annual revenues of $41.7 million in FY 2025, with Q4 revenue reaching $17.1 million, representing a 36% increase compared to Q4 2024, highlighting the company's strong performance and growing adoption in the dermatology market.
- Acquisition Agreement Finalized: The company completed an asset purchase agreement with Biofrontera AG, acquiring all U.S. rights and patents for Ameluz and RhodoLED, with a new royalty structure reducing rates to 12% for annual sales below $65 million and 15% above, significantly lowering the previous 25%-35% transfer pricing model.
- Positive Clinical Progress: Biofrontera submitted a supplemental NDA for sBCC with a PDUFA target action date of September 2026, and positive Phase III results for actinic keratosis, with plans to file a supplemental NDA in Q3 2026 to expand Ameluz's indications, indicating robust pipeline advancement.
- Margin Improvement: The gross profit margin improved from 58% to 82% in Q4 2025, with net income of $5.6 million compared to a net loss of $1.4 million in the prior year, and the company expects gross margins to range between 80% and 85% in 2026, reflecting successful cost structure transformation.
See More
Biofrontera to Report 2025 Financial Results on March 19
- Financial Reporting Schedule: Biofrontera will announce its financial results for the year ended December 31, 2025, after the U.S. market closes on March 19, 2026, reflecting the company's commitment to financial transparency.
- Conference Call Timing: The company will host a conference call at 10:00 AM ET on the same day to discuss the financial results and provide a business update, aiming to bolster investor confidence in the company's future prospects.
- Product Focus Area: Biofrontera specializes in photodynamic therapy (PDT), commercializing the drug-device combination Ameluz® with the RhodoLED® lamp series for treating precancerous skin lesions, showcasing its expertise in dermatological treatments.
- Clinical Trial Expansion: The company is conducting clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate-to-severe acne, indicating its proactive approach to product development and market expansion potential.
See More
Biofrontera Announces Ameluz® Clinical Trial Results
- Clinical Trial Results: Biofrontera's Phase 2b study demonstrated that Ameluz® achieved a 57.97% reduction in inflammatory acne lesions with a 3-hour incubation, significantly outperforming the control group's 36.51%, indicating the treatment's potential in acne management.
- Efficacy Assessment: In the mIGA analysis, 25% of patients treated with Ameluz® met the co-primary endpoint compared to 21.4% in the vehicle group, further validating Ameluz®'s effectiveness in improving skin conditions.
- Safety and Tolerability: Ameluz® exhibited a favorable safety profile, with treatment-related adverse events primarily consisting of mild to moderate burning sensations and pruritus, and average pain scores during the 3-hour treatments ranged from 3.4 to 3.8, indicating good tolerability.
- Market Potential: Acne vulgaris is one of the most common dermatological conditions in the U.S., and Biofrontera plans to present these findings to the FDA in Q3 2026 to seek approval for Ameluz® in treating moderate to severe acne, thereby expanding its dermatology product line.
See More
BIOFRONTERA INC PLANS TO SUBMIT PHASE 2B DATA FOR AMELUZ PDT TO FDA IN Q3 2026
Project Overview: The BioFrontier AI initiative is set to present Phase 2 data for the Ameluz PDT treatment in Q3 2026.
Focus on Ameluz: The data presentation will specifically highlight the efficacy and outcomes of Ameluz in photodynamic therapy (PDT).
See More
BIOFRONTERA INC - AMELUZ PDT SHOWS POSITIVE SAFETY RESULTS IN PHASE 2B TRIAL
Study Overview: A Phase 2 study by BioFrontier AI demonstrates a favorable safety profile for a new treatment.
Implications for Treatment: The findings suggest potential advancements in therapeutic options based on the study's results.
See More
Biofrontera Reports Record Q4 2025 Revenue of $17.1M
- Significant Revenue Growth: Biofrontera reported Q4 2025 revenue of $17.1 million, a 36% year-over-year increase, indicating strong market demand and sales performance, which further solidifies its position in the dermatology treatment sector.
- Gross Margin Improvement: The company achieved a gross margin of 82.4%, primarily due to an improved cost structure following its transaction with Biofrontera AG, which not only enhances profitability but also provides funding for future investments and expansion.
- Net Income Turnaround: The net income for Q4 was $5.6 million, compared to a loss in the previous year, reflecting improved operational efficiency and financial health, which boosts investor confidence.
- Positive Future Outlook: Management expects to achieve profitability and cash flow breakeven in 2026, indicating confidence in sustained growth and plans to optimize operations and market strategies to reach this goal.
See More
Biofrontera Reports Record Revenue in FY 2025 Earnings Call
- Significant Revenue Growth: Biofrontera achieved record annual revenues of $41.7 million in FY 2025, with Q4 revenue reaching $17.1 million, representing a 36% increase compared to Q4 2024, highlighting the company's strong performance and growing adoption in the dermatology market.
- Acquisition Agreement Finalized: The company completed an asset purchase agreement with Biofrontera AG, acquiring all U.S. rights and patents for Ameluz and RhodoLED, with a new royalty structure reducing rates to 12% for annual sales below $65 million and 15% above, significantly lowering the previous 25%-35% transfer pricing model.
- Positive Clinical Progress: Biofrontera submitted a supplemental NDA for sBCC with a PDUFA target action date of September 2026, and positive Phase III results for actinic keratosis, with plans to file a supplemental NDA in Q3 2026 to expand Ameluz's indications, indicating robust pipeline advancement.
- Margin Improvement: The gross profit margin improved from 58% to 82% in Q4 2025, with net income of $5.6 million compared to a net loss of $1.4 million in the prior year, and the company expects gross margins to range between 80% and 85% in 2026, reflecting successful cost structure transformation.
See More
Biofrontera to Report 2025 Financial Results on March 19
- Financial Reporting Schedule: Biofrontera will announce its financial results for the year ended December 31, 2025, after the U.S. market closes on March 19, 2026, reflecting the company's commitment to financial transparency.
- Conference Call Timing: The company will host a conference call at 10:00 AM ET on the same day to discuss the financial results and provide a business update, aiming to bolster investor confidence in the company's future prospects.
- Product Focus Area: Biofrontera specializes in photodynamic therapy (PDT), commercializing the drug-device combination Ameluz® with the RhodoLED® lamp series for treating precancerous skin lesions, showcasing its expertise in dermatological treatments.
- Clinical Trial Expansion: The company is conducting clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate-to-severe acne, indicating its proactive approach to product development and market expansion potential.
See More
Biofrontera Announces Ameluz® Clinical Trial Results
- Clinical Trial Results: Biofrontera's Phase 2b study demonstrated that Ameluz® achieved a 57.97% reduction in inflammatory acne lesions with a 3-hour incubation, significantly outperforming the control group's 36.51%, indicating the treatment's potential in acne management.
- Efficacy Assessment: In the mIGA analysis, 25% of patients treated with Ameluz® met the co-primary endpoint compared to 21.4% in the vehicle group, further validating Ameluz®'s effectiveness in improving skin conditions.
- Safety and Tolerability: Ameluz® exhibited a favorable safety profile, with treatment-related adverse events primarily consisting of mild to moderate burning sensations and pruritus, and average pain scores during the 3-hour treatments ranged from 3.4 to 3.8, indicating good tolerability.
- Market Potential: Acne vulgaris is one of the most common dermatological conditions in the U.S., and Biofrontera plans to present these findings to the FDA in Q3 2026 to seek approval for Ameluz® in treating moderate to severe acne, thereby expanding its dermatology product line.
See More
BIOFRONTERA INC PLANS TO SUBMIT PHASE 2B DATA FOR AMELUZ PDT TO FDA IN Q3 2026
Project Overview: The BioFrontier AI initiative is set to present Phase 2 data for the Ameluz PDT treatment in Q3 2026.
Focus on Ameluz: The data presentation will specifically highlight the efficacy and outcomes of Ameluz in photodynamic therapy (PDT).
See More
BIOFRONTERA INC - AMELUZ PDT SHOWS POSITIVE SAFETY RESULTS IN PHASE 2B TRIAL
Study Overview: A Phase 2 study by BioFrontier AI demonstrates a favorable safety profile for a new treatment.
Implications for Treatment: The findings suggest potential advancements in therapeutic options based on the study's results.
See More
